193 related articles for article (PubMed ID: 28828438)
1. Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Bhattacharyya J; Ren XR; Mook RA; Wang J; Spasojevic I; Premont RT; Li X; Chilkoti A; Chen W
Nanoscale; 2017 Aug; 9(34):12709-12717. PubMed ID: 28828438
[TBL] [Abstract][Full Text] [Related]
2. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Zeyada MS; Abdel-Rahman N; El-Karef A; Yahia S; El-Sherbiny IM; Eissa LA
Life Sci; 2020 Nov; 261():118458. PubMed ID: 32961231
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
4. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Ma R; Ma ZG; Gao JL; Tai Y; Li LJ; Zhu HB; Li L; Dong DL; Sun ZJ
J Biomed Mater Res A; 2020 Jan; 108(1):30-38. PubMed ID: 31433913
[TBL] [Abstract][Full Text] [Related]
5. Redox-sensitive nanoparticles based on xylan-lipoic acid conjugate for tumor targeted drug delivery of niclosamide in cancer therapy.
Sauraj ; Kumar A; Kumar B; Kulshreshtha A; Negi YS
Carbohydr Res; 2021 Jan; 499():108222. PubMed ID: 33401229
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
7. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
8. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
9. Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
[TBL] [Abstract][Full Text] [Related]
10. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
12. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
14. Small molecule modulators of Wnt/β-catenin signaling.
Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
[TBL] [Abstract][Full Text] [Related]
15. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
18. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
[TBL] [Abstract][Full Text] [Related]
19. Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer
Wang W; Li Y; Chen Y; Chen H; Zhu P; Xu M; Wang H; Wu M; Yang Z; Hoffman RM; Gu Y
Anticancer Res; 2018 Apr; 38(4):1917-1925. PubMed ID: 29599307
[TBL] [Abstract][Full Text] [Related]
20. Fortified anti-proliferative activity of niclosamide for breast cancer treatment: In-vitro and in-vivo assessment.
Mansour A; Mahmoud MY; Bakr AF; Ghoniem MG; Adam FA; El-Sherbiny IM
Life Sci; 2023 Mar; 316():121379. PubMed ID: 36623765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]